{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:58:21Z","timestamp":1791838701291,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82090014"],"award-info":[{"award-number":["82090014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of the Tibet Autonomous Region","award":["XZ2021ZR-ZY19(Z)"],"award-info":[{"award-number":["XZ2021ZR-ZY19(Z)"]}]},{"name":"Innovation& Transfer Fund of Peking University Third Hospital","award":["Y82499-07"],"award-info":[{"award-number":["Y82499-07"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-11960-5","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T04:08:03Z","timestamp":1753070883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lysophospholipid metabolism, clinical characteristics, and artificial intelligence-based quantitative assessments of chest CT in patients with stable COPD and healthy smokers"],"prefix":"10.1038","volume":"15","author":[{"given":"Qiqiang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lvxinhe","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianba","family":"Qiongda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilang","family":"ChuTso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"11960_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. Updated 2025. [Accessed 9 January 2025]. Available from URL:https:\/\/goldcopd.org\/2025-gold-report\/."},{"key":"11960_CR2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1183\/09031936.06.00025805","volume":"27","author":"AD Lopez","year":"2006","unstructured":"Lopez, A. D. et al. Chronic obstructive pulmonary disease: Current burden and future projections. Eur. Respir. J. 27, 397\u2013412. https:\/\/doi.org\/10.1183\/09031936.06.00025805 (2006).","journal-title":"Eur. Respir. J."},{"key":"11960_CR3","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1164\/rccm.201502-0223OC","volume":"192","author":"MA Sze","year":"2015","unstructured":"Sze, M. A. et al. Host response to the lung microbiome in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 192, 438\u2013445. https:\/\/doi.org\/10.1164\/rccm.201502-0223OC (2015).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"11960_CR4","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1056\/NEJMoa1007285","volume":"364","author":"GR Washko","year":"2011","unstructured":"Washko, G. R. et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N. Engl. J. Med. 364, 897\u2013906. https:\/\/doi.org\/10.1056\/NEJMoa1007285 (2011).","journal-title":"N. Engl. J. Med."},{"key":"11960_CR5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jama.2016.0518","volume":"315","author":"RK Putman","year":"2016","unstructured":"Putman, R. K. et al. Association between interstitial lung abnormalities and all-cause mortality. JAMA 315, 672\u2013681. https:\/\/doi.org\/10.1001\/jama.2016.0518 (2016).","journal-title":"JAMA"},{"key":"11960_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1164\/rccm.202203-0550OC","volume":"207","author":"JA Rose","year":"2023","unstructured":"Rose, J. A. et al. Suspected interstitial lung disease in COPDGene study. Am. J. Respir. Crit. Care Med. 207, 60\u201368. https:\/\/doi.org\/10.1164\/rccm.202203-0550OC (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"11960_CR7","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1164\/rccm.202211-2098OC","volume":"208","author":"SY Ash","year":"2023","unstructured":"Ash, S. Y., Choi, B., Oh, A., Lynch, D. A. & Humphries, S. M. Deep learning assessment of progression of emphysema and fibrotic interstitial lung abnormality. Am. J. Respir. Crit. Care Med. 208, 666\u2013675. https:\/\/doi.org\/10.1164\/rccm.202211-2098OC (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"11960_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1164\/rccm.201809-1652OC","volume":"200","author":"RK Putman","year":"2019","unstructured":"Putman, R. K. et al. Imaging patterns are associated with interstitial lung abnormality progression and mortality. Am. J. Respir. Crit. Care Med. 200, 175\u2013183. https:\/\/doi.org\/10.1164\/rccm.201809-1652OC (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"11960_CR9","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1164\/rccm.201206-1113OC","volume":"186","author":"M Thomsen","year":"2012","unstructured":"Thomsen, M., Dahl, M., Lange, P., Vestbo, J. & Nordestgaard, B. G. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 186, 982\u2013988. https:\/\/doi.org\/10.1164\/rccm.201206-1113OC (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"11960_CR10","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/thx.2009.130260","volume":"65","author":"NJ Sinden","year":"2010","unstructured":"Sinden, N. J. & Stockley, R. A. Systemic inflammation and comorbidity in COPD: A result of \u2018overspill\u2019 of inflammatory mediators from the lungs? Review of the evidence. Thorax 65, 930\u2013936. https:\/\/doi.org\/10.1136\/thx.2009.130260 (2010).","journal-title":"Thorax"},{"key":"11960_CR11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1164\/rccm.200604-506OC","volume":"174","author":"JR Hurst","year":"2006","unstructured":"Hurst, J. R. et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 174, 867\u2013874. https:\/\/doi.org\/10.1164\/rccm.200604-506OC (2006).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"11960_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2147\/copd.S240720","volume":"15","author":"A Nu\u00f1ez","year":"2020","unstructured":"Nu\u00f1ez, A. et al. Association between routine blood biomarkers and clinical phenotypes and exacerbations in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 15, 681\u2013690. https:\/\/doi.org\/10.2147\/copd.S240720 (2020).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"11960_CR13","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2147\/copd.S196210","volume":"14","author":"H Chen","year":"2019","unstructured":"Chen, H. et al. Lipid metabolism in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 14, 1009\u20131018. https:\/\/doi.org\/10.2147\/copd.S196210 (2019).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"11960_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/metabo14060317","author":"Q Zhou","year":"2024","unstructured":"Zhou, Q., Chen, Y., Liang, Y. & Sun, Y. The role of lysophospholipid metabolites LPC and LPA in the pathogenesis of chronic obstructive pulmonary disease. Metabolites https:\/\/doi.org\/10.3390\/metabo14060317 (2024).","journal-title":"Metabolites"},{"key":"11960_CR15","doi-asserted-by":"publisher","first-page":"17132","DOI":"10.1038\/s41598-018-35372-w","volume":"8","author":"CI Cruickshank-Quinn","year":"2018","unstructured":"Cruickshank-Quinn, C. I. et al. Metabolomics and transcriptomics pathway approach reveals outcome-specific perturbations in COPD. Sci. Rep. 8, 17132. https:\/\/doi.org\/10.1038\/s41598-018-35372-w (2018).","journal-title":"Sci. Rep."},{"key":"11960_CR16","doi-asserted-by":"publisher","first-page":"1204985","DOI":"10.3389\/fmolb.2023.1204985","volume":"10","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Differences in the lipid metabolism profile and clinical characteristics between eosinophilic and non-eosinophilic acute exacerbation of chronic obstructive pulmonary disease. Front. Mol. Biosci. 10, 1204985. https:\/\/doi.org\/10.3389\/fmolb.2023.1204985 (2023).","journal-title":"Front. Mol. Biosci."},{"key":"11960_CR17","doi-asserted-by":"publisher","first-page":"119816","DOI":"10.1016\/j.cca.2024.119816","volume":"561","author":"Q Zhou","year":"2024","unstructured":"Zhou, Q. et al. Comparative analysis of lysophospholipid metabolism profiles and clinical characteristics in patients with high vs low C-reactive protein levels in acute exacerbations of chronic obstructive pulmonary disease. Clin. Chim. Acta 561, 119816. https:\/\/doi.org\/10.1016\/j.cca.2024.119816 (2024).","journal-title":"Clin. Chim. Acta"},{"key":"11960_CR18","doi-asserted-by":"publisher","first-page":"19819","DOI":"10.1038\/s41598-022-24406-z","volume":"12","author":"K Saito","year":"2022","unstructured":"Saito, K. et al. Identification and characterization of lysophosphatidylcholine 14:0 as a biomarker for drug-induced lung disease. Sci. Rep. 12, 19819. https:\/\/doi.org\/10.1038\/s41598-022-24406-z (2022).","journal-title":"Sci. Rep."},{"key":"11960_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s41043-023-00400-7","volume":"42","author":"L Shi","year":"2023","unstructured":"Shi, L. et al. Novel lipidomes profile and clinical phenotype identified in pneumoconiosis patients. J. Health Popul. Nutr. 42, 55. https:\/\/doi.org\/10.1186\/s41043-023-00400-7 (2023).","journal-title":"J. Health Popul. Nutr."},{"issue":"882","key":"11960_CR20","doi-asserted-by":"publisher","first-page":"e885","DOI":"10.1016\/j.jcrc.2014.05.003","volume":"29","author":"DW Park","year":"2014","unstructured":"Park, D. W. et al. Impact of serial measurements of lysophosphatidylcholine on 28-day mortality prediction in patients admitted to the intensive care unit with severe sepsis or septic shock. J. Crit. Care 29(882), e885\u2013e811. https:\/\/doi.org\/10.1016\/j.jcrc.2014.05.003 (2014).","journal-title":"J. Crit. Care"},{"key":"11960_CR21","doi-asserted-by":"publisher","first-page":"102556","DOI":"10.1016\/j.redox.2022.102556","volume":"58","author":"W Nan","year":"2022","unstructured":"Nan, W. et al. Myristoyl lysophosphatidylcholine is a biomarker and potential therapeutic target for community-acquired pneumonia. Redox Biol. 58, 102556. https:\/\/doi.org\/10.1016\/j.redox.2022.102556 (2022).","journal-title":"Redox Biol."},{"key":"11960_CR22","doi-asserted-by":"publisher","first-page":"e1069","DOI":"10.1002\/ctm2.1069","volume":"12","author":"M Kurano","year":"2022","unstructured":"Kurano, M. et al. Dynamic modulations of sphingolipids and glycerophospholipids in COVID-19. Clin. Transl. Med. 12, e1069. https:\/\/doi.org\/10.1002\/ctm2.1069 (2022).","journal-title":"Clin. Transl. Med."},{"key":"11960_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1476-511X-6-17","volume":"6","author":"LA Taylor","year":"2007","unstructured":"Taylor, L. A., Arends, J., Hodina, A. K., Unger, C. & Massing, U. Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids Health Dis. 6, 17. https:\/\/doi.org\/10.1186\/1476-511X-6-17 (2007).","journal-title":"Lipids Health Dis."},{"key":"11960_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10096-014-2234-4","volume":"34","author":"WH Cho","year":"2015","unstructured":"Cho, W. H. et al. Lysophosphatidylcholine as a prognostic marker in community-acquired pneumonia requiring hospitalization: A pilot study. Eur. J. Clin. Microbiol. Infect. Dis. 34, 309\u2013315. https:\/\/doi.org\/10.1007\/s10096-014-2234-4 (2015).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"11960_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/s13054-020-03147-3","volume":"24","author":"MM Banoei","year":"2020","unstructured":"Banoei, M. M. et al. Plasma lipid profiling for the prognosis of 90-day mortality, in-hospital mortality, ICU admission, and severity in bacterial community-acquired pneumonia (CAP). Crit. Care 24, 461. https:\/\/doi.org\/10.1186\/s13054-020-03147-3 (2020).","journal-title":"Crit. Care"},{"key":"11960_CR26","doi-asserted-by":"publisher","first-page":"20391","DOI":"10.1038\/srep20391","volume":"6","author":"M Ferrario","year":"2016","unstructured":"Ferrario, M. et al. Mortality prediction in patients with severe septic shock: A pilot study using a target metabolomics approach. Sci. Rep. 6, 20391. https:\/\/doi.org\/10.1038\/srep20391 (2016).","journal-title":"Sci. Rep."},{"key":"11960_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejphar.2019.02.038","volume":"852","author":"H Quan","year":"2019","unstructured":"Quan, H. et al. Stearoyl lysophosphatidylcholine inhibits LPS-induced extracellular release of HMGB1 through the G2A\/calcium\/CaMKK\u03b2\/AMPK pathway. Eur. J. Pharmacol. 852, 125\u2013133. https:\/\/doi.org\/10.1016\/j.ejphar.2019.02.038 (2019).","journal-title":"Eur. J. Pharmacol."},{"key":"11960_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.intimp.2016.07.014","volume":"39","author":"H Quan","year":"2016","unstructured":"Quan, H. et al. Stearoyl lysophosphatidylcholine enhances the phagocytic ability of macrophages through the AMP-activated protein kinase\/p38 mitogen activated protein kinase pathway. Int. Immunopharmacol. 39, 328\u2013334. https:\/\/doi.org\/10.1016\/j.intimp.2016.07.014 (2016).","journal-title":"Int. Immunopharmacol."},{"key":"11960_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nm989","volume":"10","author":"JJ Yan","year":"2004","unstructured":"Yan, J. J. et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat. Med. 10, 161\u2013167. https:\/\/doi.org\/10.1038\/nm989 (2004).","journal-title":"Nat. Med."},{"key":"11960_CR30","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3389\/fimmu.2018.00920","volume":"9","author":"HJ Lee","year":"2018","unstructured":"Lee, H. J., Ko, H. J., Song, D. K. & Jung, Y. J. Lysophosphatidylcholine promotes phagosome maturation and regulates inflammatory mediator production through the protein kinase a-phosphatidylinositol 3 kinase-p38 mitogen-activated protein kinase signaling pathway during mycobacterium tuberculosis infection in mouse macrophages. Front. Immunol. 9, 920. https:\/\/doi.org\/10.3389\/fimmu.2018.00920 (2018).","journal-title":"Front. Immunol."},{"key":"11960_CR31","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.3390\/toxins6092840","volume":"6","author":"J Rolin","year":"2014","unstructured":"Rolin, J., Vego, H. & Maghazachi, A. A. Oxidized lipids and lysophosphatidylcholine induce the chemotaxis, up-regulate the expression of CCR9 and CXCR4 and abrogate the release of IL-6 in human monocytes. Toxins 6, 2840\u20132856. https:\/\/doi.org\/10.3390\/toxins6092840 (2014).","journal-title":"Toxins"},{"key":"11960_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10753-010-9218-z","volume":"34","author":"ND Hung","year":"2011","unstructured":"Hung, N. D., Kim, M. R. & Sok, D. E. Oral administration of 2-docosahexaenoyl lysophosphatidylcholine displayed anti-inflammatory effects on zymosan A-induced peritonitis. Inflammation 34, 147\u2013160. https:\/\/doi.org\/10.1007\/s10753-010-9218-z (2011).","journal-title":"Inflammation"},{"key":"11960_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bioactmat.2024.02.025","volume":"36","author":"T Xiao","year":"2024","unstructured":"Xiao, T. et al. Tailoring therapeutics via a systematic beneficial elements comparison between photosynthetic bacteria-derived OMVs and extruded nanovesicles. Bioact. Mater. 36, 48\u201361. https:\/\/doi.org\/10.1016\/j.bioactmat.2024.02.025 (2024).","journal-title":"Bioact. Mater."},{"key":"11960_CR34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jnr.21821","volume":"87","author":"Y Ikeno","year":"2009","unstructured":"Ikeno, Y. et al. Lysophosphatidylcholine protects cerebellar granule neurons from apoptotic cell death. J. Neurosci. Res. 87, 190\u2013199. https:\/\/doi.org\/10.1002\/jnr.21821 (2009).","journal-title":"J. Neurosci. Res."},{"key":"11960_CR35","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1148\/radiol.2015141579","volume":"277","author":"DA Lynch","year":"2015","unstructured":"Lynch, D. A. et al. CT-definable subtypes of chronic obstructive pulmonary disease: A statement of the fleischner society. Radiology 277, 192\u2013205. https:\/\/doi.org\/10.1148\/radiol.2015141579 (2015).","journal-title":"Radiology"},{"key":"11960_CR36","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMoa1106955","volume":"365","author":"JE McDonough","year":"2011","unstructured":"McDonough, J. E. et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N. Engl. J. Med. 365, 1567\u20131575. https:\/\/doi.org\/10.1056\/NEJMoa1106955 (2011).","journal-title":"N. Engl. J. Med."},{"key":"11960_CR37","doi-asserted-by":"publisher","first-page":"105598","DOI":"10.1016\/j.biocel.2019.105598","volume":"116","author":"PJ Barnes","year":"2019","unstructured":"Barnes, P. J. Small airway fibrosis in COPD. Int. J. Biochem. Cell Biol. 116, 105598. https:\/\/doi.org\/10.1016\/j.biocel.2019.105598 (2019).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"11960_CR38","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/copd.S392349","volume":"18","author":"Y Liu","year":"2023","unstructured":"Liu, Y., Tang, J. & Sun, Y. Impact of interstitial lung abnormalities on disease expression and outcomes in COPD or emphysema: A systematic review. Int. J. Chron. Obstruct. Pulmon. Dis. 18, 189\u2013206. https:\/\/doi.org\/10.2147\/copd.S392349 (2023).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"11960_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.acra.2023.04.026","volume":"31","author":"R Li","year":"2024","unstructured":"Li, R., Song, M., Wang, R., Su, N. & Linning, E. Can CT-based arterial and venous morphological markers of chronic obstructive pulmonary disease explain pulmonary vascular remodeling?. Acad. Radiol. 31, 22\u201334. https:\/\/doi.org\/10.1016\/j.acra.2023.04.026 (2024).","journal-title":"Acad. Radiol."},{"key":"11960_CR40","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/1471-2105-14-338","volume":"14","author":"G Nyamundanda","year":"2013","unstructured":"Nyamundanda, G., Gormley, I. C., Fan, Y., Gallagher, W. M. & Brennan, L. MetSizeR: Selecting the optimal sample size for metabolomic studies using an analysis based approach. BMC Bioinform. 14, 338. https:\/\/doi.org\/10.1186\/1471-2105-14-338 (2013).","journal-title":"BMC Bioinform."},{"key":"11960_CR41","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1183\/09031936.00102509","volume":"34","author":"PW Jones","year":"2009","unstructured":"Jones, P. W. et al. Development and first validation of the COPD assessment test. Eur. Respir. J. 34, 648\u2013654. https:\/\/doi.org\/10.1183\/09031936.00102509 (2009).","journal-title":"Eur. Respir. J."},{"key":"11960_CR42","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/thx.54.7.581","volume":"54","author":"JC Bestall","year":"1999","unstructured":"Bestall, J. C. et al. Usefulness of the medical research council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54, 581\u2013586. https:\/\/doi.org\/10.1136\/thx.54.7.581 (1999).","journal-title":"Thorax"},{"key":"11960_CR43","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1183\/09031936.05.00034805","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller, M. R. et al. Standardisation of spirometry. Eur. Respir. J. 26, 319\u2013338. https:\/\/doi.org\/10.1183\/09031936.05.00034805 (2005).","journal-title":"Eur. Respir. J."},{"key":"11960_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.media.2018.10.006","volume":"51","author":"J Yun","year":"2019","unstructured":"Yun, J. et al. Improvement of fully automated airway segmentation on volumetric computed tomographic images using a 2.5 dimensional convolutional neural net. Med. Image Anal. 51, 13\u201320. https:\/\/doi.org\/10.1016\/j.media.2018.10.006 (2019).","journal-title":"Med. Image Anal."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11960-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11960-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11960-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T04:08:06Z","timestamp":1753070886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11960-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11960"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-11960-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in strict accordance with the ethical principles set forth in the 1964 Declaration of Helsinki. The protocol was approved by the Ethics Committee of Tibet Autonomous Region People\u2019s Hospital (ME-TBHP-22\u201316). Informed consent was obtained from all participants or their legal representatives.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"26376"}}